RubrYc Therapeutics Revenue and Competitors

Founded in 2017, RubrYc Therapeutics, Inc., has created novel computational tools, chemical libraries, and analytics that confer distinct competitive advantages in the discovery of biotherapeutics. Protein interactions are the critical nodes in physiology. RubrYc has invented a unique approach, based on molecular engineering principles, to modulate therapeutically relevant protein interactions using our Interface Discovery Engineâ„¢. We integrate massively parallel in silico simulation and empirical analyses of protein structures to address long-standing challenges in biotherapeutic discovery. In therapeutic antibody discovery, epitopes matter. Our platform enables a non-conventional approach that uniquely enriches discovery campaigns with therapeutic antibody candidates that are on target, on epitope, and optimized for the prescribed mode of action. Our unique insights into protein interactions provide unprecedented opportunities to modulate historically challenging protein interactions, and access to emerging/novel targets. RubrYc Therapeutics emerged as a spin-out from HealthTell, Inc. in April 2018, announcing its rational design approach to biotherapeutic discovery using the Interface Discovery Engine. RubrYc also announced it has partnered with Third Point Ventures, iCarbonX, Paladin Capital, and Vital Venture Capital to to finance launch and initial operations.